These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 34424482)

  • 1. Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.
    Khalesi N; Korani S; Korani M; Johnston TP; Sahebkar A
    Inflammopharmacology; 2021 Oct; 29(5):1291-1306. PubMed ID: 34424482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
    Liu J; Zhao R; Jiang X; Li Z; Zhang B
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
    Dolloff NG
    Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
    Arkwright R; Pham TM; Zonder JA; Dou QP
    Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
    Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
    Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
    Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
    J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].
    Wang YR; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1584-1587. PubMed ID: 37846721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
    Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
    Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
    Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
    Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
    Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.
    Ri M
    Int J Hematol; 2016 Sep; 104(3):273-80. PubMed ID: 27169614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.